Imagenebio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Imagenebio, Inc. (Nasdaq: IMA) on July 23, 2026, reporting events occurring on July 20, 2026. The company is a Delaware corporation headquartered in San Diego, California, and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on executive appointments and compensation arrangements.
Material Changes
- Appointment of Chief Financial Officer: On July 20, 2026, the Company appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer, and principal accounting officer. She succeeds Kristin Yarema, Ph.D. (CEO), who served as interim principal financial officer.
- Executive Transition: Effective July 24, 2026, Benjamin Porter-Brown will transition from his full-time role as Chief Medical Officer to a consulting role as a clinical development expert and strategic advisor.
Compensation, Guidance, and Risks
The filing details the employment agreement and severance arrangements for the new CFO, Yanina Grant-Huerta:
- Base Salary: $450,000 annually.
- Bonus: Eligible for an annual discretionary bonus of up to 40% of base salary.
- Equity Grants:
- 65,000 Restricted Stock Units (RSUs) vesting 25% after one year, with the remainder vesting quarterly.
- 95,000 Stock Options vesting 25% after one year, with the remainder vesting monthly.
- Severance Benefits: Under the Severance and Change in Control Plan, a "covered termination" during a change in control period entitles the CFO to 12 months of base salary, 100% of the target bonus, 12 months of health benefits, and full accelerated vesting of equity. Outside a change in control, the benefit is 12 months of base salary and health benefits.
The filing does not provide updated financial guidance, management commentary on business outlook, or specific risk factors beyond standard severance plan definitions.
Investor Verification Checklist
- Verify the impact of the CFO appointment on the company's financial reporting and internal controls.
- Review the full text of the Employment Agreement (Exhibit 10.1) and Severance Plan (Exhibit 10.2) for specific definitions of "Cause" and "Good Reason."
- Assess the strategic implications of the Chief Medical Officer transitioning to a consulting role.
- Confirm the total dilution impact of the 65,000 RSUs and 95,000 stock options granted to the new CFO.